AN2 Therapeutics Raises $40 Million, Cash Runway Until 2029
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
The Company had cash, cash equivalents and investments of $85.3 million at March 31, 2026. In March 2026, AN2 raised gross proceeds of $40.0 million through a private placement, before deducting placement agent fees and other expenses. The Company projects that existing cash, cash equivalents, and investments will sustain operations into 2029 under the current operating plan. "This was an important quarter for AN2 as we announced an exciting new program in polycythemia vera that is planned to enter Phase 2 development in the third quarter of 2026. This program is supported by what we believe is a robust package of epetraborole preclinical and clinical enabling data. We commenced an investigator-initiated Phase 2 study in M. abscessus lung disease, completed dosing in a Phase 1 study for our Chagas disease program, and declared our ENPP1 candidate for the treatment of solid tumors, as well as strengthened our balance sheet," said Eric Easom, Co-Founder, Chairman, President and CEO of AN2 Therapeutics. "Looking ahead, we expect to advance three programs into Phase 2 development this year and report multiple data readouts within our cash runway into 2029. I couldn't be more excited about our progress and the potential to substantially improve the lives of patients across our diverse portfolio that is enabled by our boron chemistry pipeline."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANTX
Wall Street analysts forecast ANTX stock price to fall
4 Analyst Rating
1 Buy
2 Hold
1 Sell
Hold
Current: 4.200
Low
1.00
Averages
1.67
High
2.00
Current: 4.200
Low
1.00
Averages
1.67
High
2.00
About ANTX
AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AN2 Therapeutics Advances Chagas Disease Therapy
- Clinical Trial Results: AN2 Therapeutics demonstrated significant efficacy of its experimental therapy AN2-502998 for Chagas disease in early studies, supporting its advancement into mid-stage development, with the potential to become the first FDA-approved therapy for chronic Chagas disease in adults.
- Good Drug Tolerance: In the Phase 1 clinical trial, subjects exhibited good tolerance to AN2-502998, indicating potential safety and efficacy for future clinical applications.
- Non-Human Primate Trials: In preclinical trials involving non-human primates, AN2-502998 completely eliminated T. cruzi parasites four months post-therapy, showcasing its potential in treating chronic Chagas disease.
- Broad Market Potential: With Chagas disease affecting over 300,000 Americans, AN2 Therapeutics plans to launch a Phase 2 proof-of-concept study for AN2-502998 later this year, further advancing its commercialization efforts.
See More
AN2 Therapeutics Reports Positive Results for Chagas Disease Treatment
- Significant Efficacy: In nonhuman primates naturally infected with Trypanosoma cruzi, 28 days of AN2-502998 treatment resulted in 100% parasitic elimination, demonstrating the drug's effectiveness at exposure levels achievable in humans, indicating its potential for treating chronic Chagas disease.
- Good Safety Profile: The Phase 1 clinical trial showed that AN2-502998 was well tolerated in healthy adults with no dose-limiting toxicities, suggesting a favorable safety profile that paves the way for future clinical applications and FDA approval.
- Huge Market Opportunity: Chagas disease affects over 300,000 people in the U.S. and approximately 10 million globally, with AN2 Therapeutics estimating a multi-billion-dollar market potential for its treatment, particularly in the context of effective screening and low-cost diagnostics for high-risk populations.
- Commitment to Global Access: AN2 Therapeutics is collaborating with DNDi to ensure that AN2-502998 is accessible in Chagas-endemic regions, which, if approved, will help address the long-standing unmet medical needs in this area.
See More
AN2 THERAPEUTICS INC. TO POTENTIALLY ISSUE UP TO $80 MILLION IN COMMON STOCK THROUGH AGREEMENT WITH JEFFERIES LLC, ACCORDING TO SEC FILING
Agreement Overview: Athera Therapeutics has entered into an agreement with Jefferies LLC for a common stock offering.
Financial Details: The offering could raise up to $80 million for Athera Therapeutics.
See More
AN2 Therapeutics Reports Q4 Earnings Miss
- Earnings Report Disappointment: AN2 Therapeutics reported a Q4 GAAP EPS of -$0.29, missing the expected -$0.24, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves Status: As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $60 million, which, while providing some liquidity, raises concerns about capital efficiency and future financing needs.
- Market Reaction Expectations: Given the earnings miss, the market may adopt a cautious stance regarding AN2's growth prospects, prompting investors to closely monitor subsequent strategic adjustments and financial health.
- Analyst Rating Dynamics: According to Seeking Alpha's Quant Rating, AN2 Therapeutics' investment rating may be affected by its financial performance, leading analysts to potentially reassess its future investment value.
See More
AN2 Therapeutics Plans to Sell 8 Million Shares at $2.85 Each
- Private Placement Announcement: AN2 Therapeutics plans to sell 8.25 million shares of common stock at $2.85 each, aiming to raise approximately $40 million, with participation from institutional investors like Coastlands Capital, Commodore Capital, and Vivo Capital, indicating strong market confidence in its blood cancer treatment.
- Stock Surge: Following the announcement of positive clinical results for its blood cancer drug epetraborole, AN2 Therapeutics' stock has skyrocketed over 500% in four trading sessions, with a more than 110% increase on Monday alone, marking the largest single-day gain in its history and reflecting investor optimism about future developments.
- Clinical Trial Progress: The company plans to initiate a Phase 2 clinical trial for patients with Polycythemia Vera in Q3 2026 and expects to provide initial trial updates in the following quarter, potentially validating the drug's efficacy and safety, which could enhance the company's market performance.
- Market Sentiment Analysis: Retail sentiment on Stocktwits has remained extremely bullish over the past 24 hours, with high message volumes, as some users speculate the stock could rise to $108, although others express confusion over the bullish excitement, indicating mixed views in the market regarding the stock's future trajectory.
See More
AN2 Therapeutics Shares Surge After $40 Million Financing Announcement
- Significant Financing: AN2 Therapeutics announced a $40 million private placement financing, selling 8,245,611 common shares at $2.85 each, along with pre-funded warrants, expected to close on March 10, significantly enhancing the company's financial strength to support R&D.
- Strong Stock Performance: Following the financing announcement, AN2 Therapeutics shares surged 93.68% to $5.52, reaching a new 52-week high, indicating strong market confidence in the company's future and positive investor sentiment.
- Diverse R&D Pipeline: AN2 Therapeutics is developing small molecule therapies based on its boron chemistry platform targeting various diseases, including polycythemia vera, nontuberculous mycobacterial lung disease, Chagas disease, and melioidosis, showcasing the company's broad focus in infectious and rare diseases.
- Optimistic Market Outlook: With the successful financing, AN2 is poised to accelerate its R&D efforts, particularly in early-stage oncology and infectious disease research, further enhancing its competitiveness and market position in the biopharmaceutical industry.
See More
AN2 Therapeutics Advances Chagas Disease Therapy
- Clinical Trial Results: AN2 Therapeutics demonstrated significant efficacy of its experimental therapy AN2-502998 for Chagas disease in early studies, supporting its advancement into mid-stage development, with the potential to become the first FDA-approved therapy for chronic Chagas disease in adults.
- Good Drug Tolerance: In the Phase 1 clinical trial, subjects exhibited good tolerance to AN2-502998, indicating potential safety and efficacy for future clinical applications.
- Non-Human Primate Trials: In preclinical trials involving non-human primates, AN2-502998 completely eliminated T. cruzi parasites four months post-therapy, showcasing its potential in treating chronic Chagas disease.
- Broad Market Potential: With Chagas disease affecting over 300,000 Americans, AN2 Therapeutics plans to launch a Phase 2 proof-of-concept study for AN2-502998 later this year, further advancing its commercialization efforts.
See More
AN2 Therapeutics Reports Positive Results for Chagas Disease Treatment
- Significant Efficacy: In nonhuman primates naturally infected with Trypanosoma cruzi, 28 days of AN2-502998 treatment resulted in 100% parasitic elimination, demonstrating the drug's effectiveness at exposure levels achievable in humans, indicating its potential for treating chronic Chagas disease.
- Good Safety Profile: The Phase 1 clinical trial showed that AN2-502998 was well tolerated in healthy adults with no dose-limiting toxicities, suggesting a favorable safety profile that paves the way for future clinical applications and FDA approval.
- Huge Market Opportunity: Chagas disease affects over 300,000 people in the U.S. and approximately 10 million globally, with AN2 Therapeutics estimating a multi-billion-dollar market potential for its treatment, particularly in the context of effective screening and low-cost diagnostics for high-risk populations.
- Commitment to Global Access: AN2 Therapeutics is collaborating with DNDi to ensure that AN2-502998 is accessible in Chagas-endemic regions, which, if approved, will help address the long-standing unmet medical needs in this area.
See More
AN2 THERAPEUTICS INC. TO POTENTIALLY ISSUE UP TO $80 MILLION IN COMMON STOCK THROUGH AGREEMENT WITH JEFFERIES LLC, ACCORDING TO SEC FILING
Agreement Overview: Athera Therapeutics has entered into an agreement with Jefferies LLC for a common stock offering.
Financial Details: The offering could raise up to $80 million for Athera Therapeutics.
See More
AN2 Therapeutics Reports Q4 Earnings Miss
- Earnings Report Disappointment: AN2 Therapeutics reported a Q4 GAAP EPS of -$0.29, missing the expected -$0.24, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves Status: As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $60 million, which, while providing some liquidity, raises concerns about capital efficiency and future financing needs.
- Market Reaction Expectations: Given the earnings miss, the market may adopt a cautious stance regarding AN2's growth prospects, prompting investors to closely monitor subsequent strategic adjustments and financial health.
- Analyst Rating Dynamics: According to Seeking Alpha's Quant Rating, AN2 Therapeutics' investment rating may be affected by its financial performance, leading analysts to potentially reassess its future investment value.
See More
AN2 Therapeutics Plans to Sell 8 Million Shares at $2.85 Each
- Private Placement Announcement: AN2 Therapeutics plans to sell 8.25 million shares of common stock at $2.85 each, aiming to raise approximately $40 million, with participation from institutional investors like Coastlands Capital, Commodore Capital, and Vivo Capital, indicating strong market confidence in its blood cancer treatment.
- Stock Surge: Following the announcement of positive clinical results for its blood cancer drug epetraborole, AN2 Therapeutics' stock has skyrocketed over 500% in four trading sessions, with a more than 110% increase on Monday alone, marking the largest single-day gain in its history and reflecting investor optimism about future developments.
- Clinical Trial Progress: The company plans to initiate a Phase 2 clinical trial for patients with Polycythemia Vera in Q3 2026 and expects to provide initial trial updates in the following quarter, potentially validating the drug's efficacy and safety, which could enhance the company's market performance.
- Market Sentiment Analysis: Retail sentiment on Stocktwits has remained extremely bullish over the past 24 hours, with high message volumes, as some users speculate the stock could rise to $108, although others express confusion over the bullish excitement, indicating mixed views in the market regarding the stock's future trajectory.
See More
AN2 Therapeutics Shares Surge After $40 Million Financing Announcement
- Significant Financing: AN2 Therapeutics announced a $40 million private placement financing, selling 8,245,611 common shares at $2.85 each, along with pre-funded warrants, expected to close on March 10, significantly enhancing the company's financial strength to support R&D.
- Strong Stock Performance: Following the financing announcement, AN2 Therapeutics shares surged 93.68% to $5.52, reaching a new 52-week high, indicating strong market confidence in the company's future and positive investor sentiment.
- Diverse R&D Pipeline: AN2 Therapeutics is developing small molecule therapies based on its boron chemistry platform targeting various diseases, including polycythemia vera, nontuberculous mycobacterial lung disease, Chagas disease, and melioidosis, showcasing the company's broad focus in infectious and rare diseases.
- Optimistic Market Outlook: With the successful financing, AN2 is poised to accelerate its R&D efforts, particularly in early-stage oncology and infectious disease research, further enhancing its competitiveness and market position in the biopharmaceutical industry.
See More
